ログイン

HEMATOLOGY PRE-TEST

HEMATOLOGY PRE-TEST
32問 • 1年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    For adult capillary puncture: a. Index finger b. Ring finger c. Index or ring finger d. Middle or ring finger

    d. Middle or ring finger

  • 2

    The tourniquet should be applied above the venipuncture sl!e? a. 1to 2inches b. 3 to 4 inches c. 6 to 8 inches d. 10 to 12 inches

    b. 3 to 4 inches

  • 3

    Proper application of the tourniquet: a. Like a ribbon b. Loop toward the shoulder c. Ends pointed towards the shoulder d. Ends pointed away from the shoulder

    c. Ends pointed towards the shoulder

  • 4

    Blood pressure cuffs can be used as tourniquets. They are used primarily for veins that are difficult to locate. The cuff should be inflated to a pressure of: a. 40 mm Hg b. 80 mm Hg c. 100 mm Hg d. 120 mm Hg

    a. 40 mm Hg

  • 5

    AccuVein is a handheld medical device that helps medical staff visualize veins before phlebotomy. The device emits light and is held 7 INCHES OVER THE POTENTIAL PHLEBOTOMY SITE. a. Visible light b. Ultraviolet light ¢. Infrared light d. UV and infrared light

    ¢. Infrared light

  • 6

    Select the needle most commonly used in standard venipuncture in an adult: a. One inch, 18 gauge b. One inch, 21 gauge c. One-half inch, 23 gauge d. One-half inch, 25 gauge

    b. One inch, 21 gauge

  • 7

    Higher temperatures can cause: a. Decrease in blood draw volume b. Increase in blood draw volume c. Both of these d. None of these

    a. Decrease in blood draw volume

  • 8

    High altitude: a. Decrease in blood draw volume b. Increase in blood draw volume c. Both of these d. None of these

    a. Decrease in blood draw volume

  • 9

    Resting phase: a. Anaphase b. Interphase ¢. Metaphase d. Telophase

    b. Interphase

  • 10

    The cell selected for chromosome analysis is usually in the stage of cellular division. a. Prophase b. Metaphase c. Anaphase d. Telophase

    b. Metaphase

  • 11

    A patient has a hemoglobin of 12.3 g/dL. What is the expected range for the patient’s hematocrit? a. 41.0% b. 36.9% c.24.6% d.NOTA

    b. 36.9%

  • 12

    Human hematopoietic stem cells express: a. CD3 b.CD10 c. CD34 d. CD56

    c. CD34

  • 13

    Erythropoietin s primarily produced by the: a. Kidney b. Bone marrow c. Yolk sac d. Red cells

    a. Kidney

  • 14

    The average diameter of a normal erythrocyteis _____ um. a. 5.2 b.6.4 c.7.2 d.8.4

    c.7.2

  • 15

    The average adult has g of total iron. a. 0.2 t 0 1.4 b.1.5 t0 3.4 c.3.5 tO 5.0 d.5.1 TO 10.0

    c.3.5 tO 5.0

  • 16

    Severe increase in abnormal erythrocytes in each microscopic field; an equivalent descriptive term is MANY: a. 1+ b. 2+ c. 3+ d. 4+

    c. 3+

  • 17

    RBC with membrane folded over: a. Aplastic anemia b. Iron deficiency anemia ¢. Hemoglobin C, hemoglobin SC disease d. Sickle cell anemia, thalassemia

    ¢. Hemoglobin C, hemoglobin SC disease

  • 18

    Increased ESR: a. Hyperalbuminemia b. Hyperfibrinogenemia ¢. Microcytosis d. Polycythemia

    b. Hyperfibrinogenemia

  • 19

    The RDW and MCV are both quantitative descriptors of erythrocyte size. If both are increased, the most probable erythrocytic abnormality would be: a. Iron deficiency anemia b. Acquired aplastic anemia ¢. Megaloblastic anemia d. Hemoglobinopathy

    ¢. Megaloblastic anemia

  • 20

    Lazy leukocyte syndrome involves which cell type? a. Erythrocytic series b. Monocyte-macrophage series c. Neutrophilic series d. Platelet series

    c. Neutrophilic series

  • 21

    Cells have distinctive nuclear lobulation and have been termed “flower cells” a. Acute myelogenous leukemia b. Adult T cell leukemia/lymphoma c. Hairy cell leukemia d. Hodgkin's lymphoma

    b. Adult T cell leukemia/lymphoma

  • 22

    What reagents are used in the PT test? a. Thromboplastin and sodium chloride b. Thromboplastin and potassium chloride ¢. Thromboplastin and calcium d. Actin and calcium chloride

    ¢. Thromboplastin and calcium

  • 23

    The function of thromboplastin in the prothrombin test is to provide ____ to the assay. a. Kaolin b. Fibrinogen c. Phospholipoprotein d. Thrombin

    c. Phospholipoprotein

  • 24

    If a child ingested rat poison, which of the following test should be performed to test the effect of the poison on a. APTT b. PT c. Fibrinogen assay d. Thrombin time

    b. PT

  • 25

    Reference values for PTT in adults: a. 12 to 14 seconds b. 13 to 15 seconds c. 25 to 35 seconds d. 1 to 2 minutes

    c. 25 to 35 seconds

  • 26

    Typical PTT therapeutic range: a. 10 to 15 seconds b. 20 to 40 seconds c. 60 to 100 seconds d. 100 to 150 seconds

    c. 60 to 100 seconds

  • 27

    A fresh blood sample was sent to the laboratory at 8:00 a.m. for a PT test. At 4:00 p.m., the doctor requested an APTT test to be done on the same sample. What should the technologist do? a. Rerun APTT on the 8:00 a.m. sample and report result b. Request a new sample for APTT c. Run APTT in duplicate and report the average d. Mix the patient plasma with normal plasma and run the APTT

    b. Request a new sample for APTT

  • 28

    A plasma sample submitted to the lab for PT testing has been stored for 25 hours at 4°C. The PT result is shortened. What is the most probable cause? a. Factor VIl deficiency b.Activation of factor VIl due to exposure to cold temperature c. Lupus inhibitor d. Factor X inhibitor

    b.Activation of factor VIl due to exposure to cold temperature

  • 29

    Hemophilia A: a. Normal PT, prolonged APTT, normal TCT b. Prolonged PT, normal APTT, normal TCT c. Prolonged PT, prolonged APTT, normal TCT d. Prolonged PT, prolonged APTT, prolonged TCT

    a. Normal PT, prolonged APTT, normal TCT

  • 30

    Factor X deficiency: a. Normal PT, prolonged APTT, normal TCT b. Normal PT, prolonged APTT, prolonged TCT c. Prolonged PT, prolonged APTT, normal TCT d. Prolonged PT, prolonged APTT, prolonged TCT

    c. Prolonged PT, prolonged APTT, normal TCT

  • 31

    Factor | deficiency: a. Normal PT, prolonged APTT, normal TCT b. Normal PT, prolonged APTT, prolonged TCT ¢. Prolonged PT, prolonged APTT, normal TCT d. Prolonged PT, prolonged APTT, prolonged TCT

    d. Prolonged PT, prolonged APTT, prolonged TCT

  • 32

    What is C in VCS technology? a. Coagulation b. Correction ¢. Conductivity d. Chronic

    ¢. Conductivity

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    For adult capillary puncture: a. Index finger b. Ring finger c. Index or ring finger d. Middle or ring finger

    d. Middle or ring finger

  • 2

    The tourniquet should be applied above the venipuncture sl!e? a. 1to 2inches b. 3 to 4 inches c. 6 to 8 inches d. 10 to 12 inches

    b. 3 to 4 inches

  • 3

    Proper application of the tourniquet: a. Like a ribbon b. Loop toward the shoulder c. Ends pointed towards the shoulder d. Ends pointed away from the shoulder

    c. Ends pointed towards the shoulder

  • 4

    Blood pressure cuffs can be used as tourniquets. They are used primarily for veins that are difficult to locate. The cuff should be inflated to a pressure of: a. 40 mm Hg b. 80 mm Hg c. 100 mm Hg d. 120 mm Hg

    a. 40 mm Hg

  • 5

    AccuVein is a handheld medical device that helps medical staff visualize veins before phlebotomy. The device emits light and is held 7 INCHES OVER THE POTENTIAL PHLEBOTOMY SITE. a. Visible light b. Ultraviolet light ¢. Infrared light d. UV and infrared light

    ¢. Infrared light

  • 6

    Select the needle most commonly used in standard venipuncture in an adult: a. One inch, 18 gauge b. One inch, 21 gauge c. One-half inch, 23 gauge d. One-half inch, 25 gauge

    b. One inch, 21 gauge

  • 7

    Higher temperatures can cause: a. Decrease in blood draw volume b. Increase in blood draw volume c. Both of these d. None of these

    a. Decrease in blood draw volume

  • 8

    High altitude: a. Decrease in blood draw volume b. Increase in blood draw volume c. Both of these d. None of these

    a. Decrease in blood draw volume

  • 9

    Resting phase: a. Anaphase b. Interphase ¢. Metaphase d. Telophase

    b. Interphase

  • 10

    The cell selected for chromosome analysis is usually in the stage of cellular division. a. Prophase b. Metaphase c. Anaphase d. Telophase

    b. Metaphase

  • 11

    A patient has a hemoglobin of 12.3 g/dL. What is the expected range for the patient’s hematocrit? a. 41.0% b. 36.9% c.24.6% d.NOTA

    b. 36.9%

  • 12

    Human hematopoietic stem cells express: a. CD3 b.CD10 c. CD34 d. CD56

    c. CD34

  • 13

    Erythropoietin s primarily produced by the: a. Kidney b. Bone marrow c. Yolk sac d. Red cells

    a. Kidney

  • 14

    The average diameter of a normal erythrocyteis _____ um. a. 5.2 b.6.4 c.7.2 d.8.4

    c.7.2

  • 15

    The average adult has g of total iron. a. 0.2 t 0 1.4 b.1.5 t0 3.4 c.3.5 tO 5.0 d.5.1 TO 10.0

    c.3.5 tO 5.0

  • 16

    Severe increase in abnormal erythrocytes in each microscopic field; an equivalent descriptive term is MANY: a. 1+ b. 2+ c. 3+ d. 4+

    c. 3+

  • 17

    RBC with membrane folded over: a. Aplastic anemia b. Iron deficiency anemia ¢. Hemoglobin C, hemoglobin SC disease d. Sickle cell anemia, thalassemia

    ¢. Hemoglobin C, hemoglobin SC disease

  • 18

    Increased ESR: a. Hyperalbuminemia b. Hyperfibrinogenemia ¢. Microcytosis d. Polycythemia

    b. Hyperfibrinogenemia

  • 19

    The RDW and MCV are both quantitative descriptors of erythrocyte size. If both are increased, the most probable erythrocytic abnormality would be: a. Iron deficiency anemia b. Acquired aplastic anemia ¢. Megaloblastic anemia d. Hemoglobinopathy

    ¢. Megaloblastic anemia

  • 20

    Lazy leukocyte syndrome involves which cell type? a. Erythrocytic series b. Monocyte-macrophage series c. Neutrophilic series d. Platelet series

    c. Neutrophilic series

  • 21

    Cells have distinctive nuclear lobulation and have been termed “flower cells” a. Acute myelogenous leukemia b. Adult T cell leukemia/lymphoma c. Hairy cell leukemia d. Hodgkin's lymphoma

    b. Adult T cell leukemia/lymphoma

  • 22

    What reagents are used in the PT test? a. Thromboplastin and sodium chloride b. Thromboplastin and potassium chloride ¢. Thromboplastin and calcium d. Actin and calcium chloride

    ¢. Thromboplastin and calcium

  • 23

    The function of thromboplastin in the prothrombin test is to provide ____ to the assay. a. Kaolin b. Fibrinogen c. Phospholipoprotein d. Thrombin

    c. Phospholipoprotein

  • 24

    If a child ingested rat poison, which of the following test should be performed to test the effect of the poison on a. APTT b. PT c. Fibrinogen assay d. Thrombin time

    b. PT

  • 25

    Reference values for PTT in adults: a. 12 to 14 seconds b. 13 to 15 seconds c. 25 to 35 seconds d. 1 to 2 minutes

    c. 25 to 35 seconds

  • 26

    Typical PTT therapeutic range: a. 10 to 15 seconds b. 20 to 40 seconds c. 60 to 100 seconds d. 100 to 150 seconds

    c. 60 to 100 seconds

  • 27

    A fresh blood sample was sent to the laboratory at 8:00 a.m. for a PT test. At 4:00 p.m., the doctor requested an APTT test to be done on the same sample. What should the technologist do? a. Rerun APTT on the 8:00 a.m. sample and report result b. Request a new sample for APTT c. Run APTT in duplicate and report the average d. Mix the patient plasma with normal plasma and run the APTT

    b. Request a new sample for APTT

  • 28

    A plasma sample submitted to the lab for PT testing has been stored for 25 hours at 4°C. The PT result is shortened. What is the most probable cause? a. Factor VIl deficiency b.Activation of factor VIl due to exposure to cold temperature c. Lupus inhibitor d. Factor X inhibitor

    b.Activation of factor VIl due to exposure to cold temperature

  • 29

    Hemophilia A: a. Normal PT, prolonged APTT, normal TCT b. Prolonged PT, normal APTT, normal TCT c. Prolonged PT, prolonged APTT, normal TCT d. Prolonged PT, prolonged APTT, prolonged TCT

    a. Normal PT, prolonged APTT, normal TCT

  • 30

    Factor X deficiency: a. Normal PT, prolonged APTT, normal TCT b. Normal PT, prolonged APTT, prolonged TCT c. Prolonged PT, prolonged APTT, normal TCT d. Prolonged PT, prolonged APTT, prolonged TCT

    c. Prolonged PT, prolonged APTT, normal TCT

  • 31

    Factor | deficiency: a. Normal PT, prolonged APTT, normal TCT b. Normal PT, prolonged APTT, prolonged TCT ¢. Prolonged PT, prolonged APTT, normal TCT d. Prolonged PT, prolonged APTT, prolonged TCT

    d. Prolonged PT, prolonged APTT, prolonged TCT

  • 32

    What is C in VCS technology? a. Coagulation b. Correction ¢. Conductivity d. Chronic

    ¢. Conductivity